Drugs / SENDEGOBRESIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05355753 | Mar 2022 → Dec 2023 | synovial sarcoma | C4 Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SENDEGOBRESIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095228 ↗ |
| Known as | CFT8634 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05355753 ↗ |
| Modality | Small molecule | — CHEMBL5095228 ↗ |
| Route | Oral | “Oral dose of CFT8634” NCT05355753 ↗ |